Comparative Pharmacology
Head-to-head clinical analysis: HY PAM 25 versus SER AP ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HY PAM 25 versus SER AP ES.
HY-PAM "25" vs SER-AP-ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
SER-AP-ES is a combination product containing reserpine (depletes catecholamines from adrenergic nerve endings), hydralazine (direct vasodilation via smooth muscle relaxation), and hydrochlorothiazide (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
SER-AP-ES is a combination antihypertensive tablet containing reserpine 0.1 mg, hydralazine hydrochloride 25 mg, and hydrochlorothiazide 15 mg. Usual adult dose: one tablet orally twice daily. Increase as needed to a maximum of two tablets twice daily.
None Documented
None Documented
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
Reserpine: 50-100h (terminal); hydralazine: 2-8h (slow acetylators 4-8h, fast 2-4h); hydrochlorothiazide: 6-15h. Context: reserpine's long t½ accounts for prolonged effects; hydralazine requires dose adjustment for acetylator status.
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Renal: 30-40% unchanged reserpine; 60-70% as metabolites (hydralazine: 50% renal, 15% fecal; hydrochlorothiazide: 95% renal unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination